A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)

ENMD-2076, an aurora-A kinase inhibitor with anti-angiogenic properties, has shown activity in solid and hematologic malignancies. We investigated oral ENMD-2076 in an open-label, single-arm phase II study using 275 mg daily on a 28-day cycle in patients with advanced soft-tissue sarcomas (STS) rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Veitch, Zachary, Zer, Alona, Loong, Herbert, Salah, Samer, Masood, Maryam, Gupta, Abha, Bradbury, Penelope A., Hogg, David, Wong, Andrew, Kandel, Rita, Charames, George S., Abdul Razak, Albiruni R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517396/
https://www.ncbi.nlm.nih.gov/pubmed/31089155
http://dx.doi.org/10.1038/s41598-019-43222-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517396/
https://www.ncbi.nlm.nih.gov/pubmed/31089155
http://dx.doi.org/10.1038/s41598-019-43222-6

Ejemplares similares